Handbook of Hypertension

摘要: Provisional Table of Contents. Abbreviations . General Introduction Hypertension Syndrome. Vascular Biology. Functional Endothelium. Endothelial Dysfunction. New Treatment Approach. Hypothesis: Essential and End-Organ Damage Classification Guidelines Wordwide in the US. JNC-7. NHANES III IV. CHS. ESH-ESC. ISHIB. AHA. BHS/NICE(RCP). JBS 2. Global Cardiovascular Risk Calculation. Secondary Hypertension. Measurement Blood Pressure Indirect measurement blood pressure. Korotkoff Sounds. Common Mistakes Measurement. Hypertension-Atherosclerotic Normotensive Pre-hypertension. Nonpharmacologic Nutrition. Nutraceuticals, Vitamins, Minerals Antioxidants. DASH I II Trials. Specific Recommendations. Obesity. Exercise. Approaches to Selection Antihypertensive Therapy Stepped Care. Demographics. Subsets Renin Profiling: The Laragh Method. Hemodynamics Hemodynamics: Logical Preferred Method Reduce Pressure. Hemodynamic Effects Drugs. Hypertension-Related Damage. Life Expectancy Systolic, Diastolic Pulse Concepts. Isolated Systolic Clinical Trials Drug Completed Progress. Diuretic Beta-Blocker Summary with Diuretics. Beta-Blockers. Meta-Analysis Various Comparisons ACE-Inhibitor therapy Placebo. Calcium-antagonist More Intensive Lowering Strategies Less. Strategies. Ace-Inhibitor based Diuretic-based or Therapy. Calcium-antagonist-based Beta-BlockerTherapy. Outcomes. Health Outcomes Meta-Analysis. Comparing CCBs other ALLHAT Trial. ALLHAT: Conclusions. ASCOT Published Involving CCBs. Angiotensin Converting Enzyme Inhibitors (ACEI) ACEI Receptor Blockers (ARBs) ARBs Summary. Coronary Heart Disease Factor Anti-hypertensive Disease: Factors. Factors: potential risk factors. Influence on CHD Drugs Serum Lipids. Lipids Diuretics and. Beta Blockers. Calcium Channel Atherosclerosis (CHD Reduction Trials). Renal Chronic Kidney Disease. Damage:. Postulated Mechanisms. Is Thiazide Diuretic-Based Associated Increased. Injury. Major Showing Renoprotection. Function. Diabetes Mellitus Hypertensive Diabetics: Mortality, Antihypertensive. BP Level Type II-DM Nephropathy. RENAAL TRIAL. Based Demographics Resistant Elderly. Urgencies Emergencies. Principles. Choice Drug. Disorders. Pregnancy. Review Quality (Selected Compliance. Total Cost Characteristics Ideal Combination Therapy: Selected Drugs: Efficacy Monotherapy. Interactions Maximum Recommended Doses Best Characteristics. all Classes Highlights. Central Alpha-Agonists. Alpha-Agonists: Similarities. Comparison Commonly Used Oral Postganglionic Neuron Inhibitors. Beta-Blockers-General. Side Contraindications Beta-Blockers Direct Vasodilators. Vasodilators Alpha1-Blockers. Alpha1-Blockers: Angiotensin-Converting (ACE) Renin-Angiotensin System (RAAS). ACE Inhibitors: Non ACEIs. Blockers: Treatment: (ARBs). Ang-II (ARBs): effects ARB's. Aldosterone Antagonists (SARA's). Statin ( Amlodipine Atorvastatin). Arterial Compliance: Structure/Function: Treatment. Selection: Classes. Subset Conclusions 383. References 385. Index 400.